TeamDrive
RUS

Russias drugs exports in January November 2017 amounted to 19 billion rubles

12 January 2018

GMP News

In the first 11 months of 2017, the exports of medicinal products from Russia (excluding the shipments to EAEU) reached 19.0 billion rubles (including the customs duties). This means that, when calculated in the Russian currency, the increase over the same period of 2016 was only 0.4%. However, the mere fact of positive dynamics is quite encouraging, as the results for January-October were much gloomier (at that time, the long-term growth rate was -2.2%).

The active efforts of exporters reversed the situation in November 2017. For that month, the total exports of medicinal products from Russia reached 2.3 billion rubles, an increase was 23% in ruble terms. Although this was not a record-breaking result, it is still quite outstanding, since better dynamics have been demonstrated by exporters only in January 2017, when the shipments increased by 58%.

In physical terms, the exports in November 2017 amounted to 70.8 million packages, a 22% increase year over year. Moreover, throughout the year, the general dynamics in physical terms can be described as rather successful. Despite occasional downturns reported, for example, for February when the exports in terms of shipped packages fell by 38%, the overall results for the first 11 months of 2017 have been markedly positive (+7.3%). Since the beginning of 2017, the total exports of medicinal products from Russia reached 536.4 million packages.


Previous publication Next publication

Media Center

  • 18 January 2018

    Russian President signs the Federal Law on introduction of drug labeling

    Russian President Vladimir Putin signed the Federal Law “On amendments to the Federal law “On Circulation of medicines.” The law provides for the establishment of state information system to monitor the movement of medicinal products for human use from the manufacturer to the final consumer by using the means of identification with regard to medicinal products in order to ensure the quality control of medicinal products for human use, that are in circulation, and protect the legal trade from falsified, counterfeit, and substandard medicines.

  • 18 January 2018

    Russia has one of the shortest periods for expert examination of medicines

    Elena Maksimkina, the Director of the Department of Drug Supply and Regulation of Medical Devices at the Russian Ministry of Health, gave her assessment of the pharmaceutical market in Russia.

  • 17 January 2018

    New tools for turning genes into drug factories

    Synthetic biologists have long dreamed of designing genetic circuits in the body that can produce drugs in response to environmental cues. But it’s been a challenging task. Now scientists at Rice University say they’ve created a toolkit of gene “promoters” that can turn genes on and off at command.

  • 17 January 2018

    FDA approves first treatment for breast cancer with a certain inherited genetic mutation

    The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.

Read more